[Use of human recombinant erythropoietin in children with cancer].
Eighty percent of children with cancer suffer from anemia at the time of diagnosis. The physiopathology of anemia is complex. Although anemia can be life threatening, its consequences on the physical, psychological and social state of the child are often minimized. Blood transfusion is the main treatment of anemia: its efficacy is immediate but shortlasting, and it involves infectious and hemolytic risks. The human recombinant erythropoietin has been used for more than 25-years, and is often prescribed to adults with cancer and anemia. The human recombinant erythropoietin rHuEPO is nowadays used when blood transfusion is contra-indicated because of religious or cultural considerations, although several promising studies have been conducted about rHuEPO and children with cancer since 1996: it might be soon the preferential alternative treatment to anemia in children with cancer.
Guyot
D
D
Service d'hématologie et oncologie pédiatrique, CHU Arnaud-de-Villeneuve, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 05, France. purotu@wanadoo.fr
Margueritte
G
G
D000293:Adolescent; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D009369:Neoplasms / Q000150:complications*; D009447:Neuroblastoma / Q000150:complications; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin